<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00416910</url>
  </required_header>
  <id_info>
    <org_study_id>GCLLSG-CLL6</org_study_id>
    <secondary_id>CDR0000455571</secondary_id>
    <secondary_id>EU-20558</secondary_id>
    <secondary_id>AMGEN-GCLLSG-CLL6</secondary_id>
    <secondary_id>MEDAC-GCLLSG-CLL6</secondary_id>
    <nct_id>NCT00416910</nct_id>
  </id_info>
  <brief_title>Combination Chemotherapy With or Without G-CSF in Treating Patients With Relapsed Chronic Lymphocytic Leukemia</brief_title>
  <official_title>Treatment of Advanced Chronic Lymphocytic Leukemia (CLL) Fludarabine, Mitoxantrone and Cyclophosphamide With or Without G-CSF</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>German CLL Study Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>German CLL Study Group</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as fludarabine, mitoxantrone, and
      cyclophosphamide, work in different ways to stop the growth of cancer cells, either by
      killing the cells or by stopping them from dividing. Giving more than one drug (combination
      chemotherapy) may kill more cancer cells. Colony stimulating factors, such as G-CSF, may
      increase the number of immune cells found in bone marrow or peripheral blood and may help the
      immune system recover from the side effects of combination chemotherapy. It is not yet known
      whether giving combination chemotherapy alone is more effective than combination chemotherapy
      together with G-CSF in treating patients with chronic lymphocytic leukemia.

      PURPOSE: This randomized phase III trial is studying giving combination chemotherapy together
      with G-CSF to see how well it works compared to giving combination chemotherapy alone in
      treating patients with relapsed stage I, stage II, stage III, or stage IV chronic lymphocytic
      leukemia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      Primary

        -  Compare the rate of remission, severe infections, and side effects in patients with
           relapsed advanced chronic lymphocytic leukemia treated with fludarabine, mitoxantrone
           hydrochloride, and cyclophosphamide with vs without filgrastim.

      Secondary

        -  Compare the overall survival, progression-free survival, and quality of remission in
           these patients.

      OUTLINE: This is a multicenter, randomized study. Patients are randomized to 1 of 2 treatment
      arms.

        -  Arm I: Patients receive fludarabine IV on days 1-3, mitoxantrone hydrochloride IV on day
           1, and cyclophosphamide IV on days 1-3.

        -  Arm II: Patients receive fludarabine, mitoxantrone hydrochloride, and cyclophosphamide
           as in arm I and filgrastim (G-CSF) beginning on day 6 and continuing until blood counts
           recover.

      In both arms, treatment repeats every 28 days for up to 6 courses in the absence of disease
      progression or unacceptable toxicity.

      PROJECTED ACCRUAL: A total of 165 patients will be accrued for this study.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    low recruitment
  </why_stopped>
  <start_date>July 1999</start_date>
  <completion_date type="Actual">September 2007</completion_date>
  <primary_completion_date type="Actual">September 2003</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">83</enrollment>
  <condition>Chronic Lymphocytic Leukemia</condition>
  <arm_group>
    <arm_group_label>FCM</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Fludarabine i.v. (25 mg/m2/d, d1-3) Cyclophosphamide i.v. (200 mg/m2/d, d1-3) Mitoxantrone i.v. (8 mg/m2, d1) q28d, max. 6 cycles</description>
  </arm_group>
  <arm_group>
    <arm_group_label>FCM + G-CSF</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fludarabine i.v. (25 mg/m2/d, d1-3) Cyclophosphamide i.v. (200 mg/m2/d, d1-3) Mitoxantrone i.v. (8 mg/m2, d1) Filgrastim (G-CSF) s.c. (5 µg/kg/d beginning on day +6 until neutrophil recovery above 1500/µl.) q28d, max. 6 cycles</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Filgrastim</intervention_name>
    <arm_group_label>FCM + G-CSF</arm_group_label>
    <other_name>Neupogen</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine</intervention_name>
    <arm_group_label>FCM</arm_group_label>
    <arm_group_label>FCM + G-CSF</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <arm_group_label>FCM</arm_group_label>
    <arm_group_label>FCM + G-CSF</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mitoxantrone</intervention_name>
    <arm_group_label>FCM</arm_group_label>
    <arm_group_label>FCM + G-CSF</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Confirmed relapsed and advanced chronic lymphocytic leukemia (CLL)

               -  Binet stage B or C disease with rapid disease progression, enlarged lymph nodes
                  and organs, or severe B-symptoms

          -  No prior non-response to fludarabine combination therapy

        PATIENT CHARACTERISTICS:

          -  ECOG performance status 0-3

          -  Life expectancy &gt; 6 months

          -  No severe organ dysfunction

          -  No other prior or concurrent neoplasm, autoimmune hemolytic anemia, or
             thrombocytopenia

        PRIOR CONCURRENT THERAPY:

          -  No more than three previous treatment regimens for CLL (fludarabine allowed)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Hallek, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medizinische Universitaetsklinik I at the University of Cologne</affiliation>
  </overall_official>
  <link>
    <url>http://www.dcllsg.de</url>
    <description>German CLL Study Group</description>
  </link>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 27, 2006</study_first_submitted>
  <study_first_submitted_qc>December 27, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 28, 2006</study_first_posted>
  <last_update_submitted>September 23, 2016</last_update_submitted>
  <last_update_submitted_qc>September 23, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 26, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>refractory chronic lymphocytic leukemia</keyword>
  <keyword>stage III chronic lymphocytic leukemia</keyword>
  <keyword>stage IV chronic lymphocytic leukemia</keyword>
  <keyword>stage I chronic lymphocytic leukemia</keyword>
  <keyword>stage II chronic lymphocytic leukemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Mitoxantrone</mesh_term>
    <mesh_term>Lenograstim</mesh_term>
    <mesh_term>Vidarabine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

